|Medical School||Columbia University College of Physicians & Surgeons (M.D. & Ph.D.)|
|Residency||Brigham Women’s Hospital (Anatomic Pathology)|
|Fellowship||University of California, San Francisco (Ophthalmic Pathology)|
|Special Interest||Ophthamic Pathology including pigmented ocular lesions (uveal melanoma, primary acquired melanosis), basal cell carcinoma, sebaceous gland lesions, inflammatory lesions (sclerosing orbital inflammatory pseudotumor, IgG4 disease), MALToma, corneas (PKPs, DSAEKs), conjunctival biopsies (conjunctival intraepithelial neoplasia - CIN), orbital lesions, intraocular fine needle aspirates/vitrectomy specimens. Cellular and molecular mechanisms of retinal degeneration. RPE and ocular stem cells.|
|Publications||View on PubMed|
Dr. Lin received his B.A. in Biochemistry from Harvard College, and his Ph.D. in Neuroscience and his M.D. in 2001, both from Columbia University College of Physicians & Surgeons. Dr. Lin completed anatomic pathology residency training at Brigham & Women's Hospital, followed by ophthalmic pathology fellowship training at UCSF, where he was a Clinical Instructor in Pathology and Ophthalmology. He joined the faculty at UCSD in 2008 where he directs the ophthalmic pathology service at UCSD Medical Center. Dr. Lin has received multiple awards and grants from the National Institutes of Health/National Eye Institute, the American Society for Investigative Pathology, and the International Society for Eye Research.
Our research program examines cellular and molecular mechanisms of retinal degeneration. We have investigated the role of oxidative and endoplasmic reticulum stress in a variety of retinal dystrophies including heritable and environmental forms of retinitis pigmentosa. We have shown that many mutant proteins that cause photoreceptor cell death such as P23H rhodopsin cause protein misfolding and endoplasmic reticulum stress in the retina. We have developed chemical, genetic, and pharmacologic tools to reduce proteotoxicity in the eye and ultimately to prevent vision loss in people with retinitis pigmentosa. We are also investigating stem cell based therapies to treat people with age-related macular degeneration and retinitis pigmentosa. These efforts are based on creating new Retinal Pigment Epithelium using endogenous stem cells in the eye as well as patient-specific induced pluripotent stem cells. These stem cell-derived retinal pigment epithelium provide a new regenerative medicine resource for transplantation in retinal diseases.
The information contained in this online site is intended to provide accurate and helpful health information for the general public. It is made available with the understanding that the author and publisher are not engaged in rendering medical, health, psychological, or any other kind of personal professional services on this site. The information should not be considered complete and does not cover all diseases, ailments, physical conditions or their treatment. It should not be used in place of a call or visit to a medical, health or other competent professional, who should be consulted before adopting any of the suggestions in this site or drawing inferences from it.
The information about drugs contained on this site is general in nature. It does not cover all possible uses, actions, precautions, side effects, or interactions of the medicines mentioned, nor is the information intended as medical advice for individual problems or for making an evaluation as to the risks and benefits of taking a particular drug.
The operator(s) of this site, and the publisher, specifically disclaim all responsibility for any liability, loss or risk, personal or otherwise, which is incurred as a consequence, directly or indirectly, of the use and application of any of the material on this site.
Click Here To Accept